- Overview
- Products
- Negative Pressure Wound Therapy
- Wound Dressings and Compression
- Skin Care
- Surgical
- Vascular Access
- Sterilization Monitoring
- Temperature Management
- Adhesive Securement
- Patient Monitoring
- Respiratory Protection
- Securement and Immobilization
- Prevention
- Pressure Injuries
- Adhesive Skin Damage
- Moisture Associated Skin Damage
- Bloodstream Infections
- Hypothermia
- Tube and Line Dislodgement
- Cross Contamination
- Electrode-Related Alarm Fatigue
- Hand Hygiene
- Treatment
- Pressure Injuries
- Diabetic Foot Ulcers
- Venous Leg Ulcers
- Traumatic Wounds
- Surgical Incisions
- Open Abdomen
- Incontinence-Associated Dermatitis
- Edema and Lymphedema
- Oncology Care
- C. difficile infection
- Resources
- Education
- Support
The Power of We.
Our apologies...
An error has occurred while submitting. Please try again later...
Thank you!
Thank you for requesting to connect with a 3M Specialist. Someone from our team will contact you soon.
-
Together. We improve. We deliver. We renew hope and strive to reduce costs.
-
At 3M, we apply science in collaborative ways to help improve lives daily. When you collaborate with 3M you will be connected with a team of professionals who are committed to meeting your product and supply needs, enabling your staff to focus on providing patient care and helping to improve patient outcomes.
-
At 3M, we never stop inventing. With an array of medical solutions, our products are designed to protect and support your patients along their surgical journey, hospital stay or clinic visit.
-
Guidance from leading clinicians, regulatory analysts, coding professionals and technology experts expands the depth of our research and technical knowledge.
-
Enhancing the patient experience is your priority — and ours. 3M products and solutions can follow the patient throughout the entire healing journey.
-
Our reliable support helps you solve product, insurance and billing issues, and our case managers provide additional transition support. Our support processes help improve supply chain efficiency and eliminate disruptions.
-
Our nationwide team of over 100 clinically-trained support specialists are ready to partner with you to transform outcomes, from wound, incision and skin care, to solutions for patient preparation and management.
-
3M provides end-to-end value-added support management — from scheduling, delivery and set up to inspection, service and documentation — that helps to lower total cost and enhance caregiver efficiency.
-
3M helps customers prevent and resolve problems in both acute and post-acute settings by reliably delivering support and service solutions. So our customers can focus on what's most important.
-
Positively impacting patient prevention
We can help reduce the risk of infections and readmissions.
- Help reduce the risk of cross contamination.¹
- 3M™ Tegaderm™ CHG Chlorhexidine Gluconate I.V. Securement Dressing is intended to reduce the risk of catheter related bloodstream infections (CRBSIs).²
- 3M™ Prevena™ Therapy* has been clinically demonstrated to aid in reducing the incidence of superficial surgical site infection in patients at high risk for post-operative infections with Class I and Class II wounds.
- We can help reduce the risk of surgical complications through an evidence-based approach to the perioperative journey.
- Studies have shown that 3M™ Veraflo™ Therapy through repeated wound cleansing and NPWT can help reduce the likelihood of complications resulting from a stalled wound.³
References:
1. CDC Vitalsigns making health care safer: Reducing bloodstream infections. Centers for Disease Control and Prevention Web site. https://www.cdc.gov/vitalsigns/pdf/2011-03- vitalsigns.pdf Published March, 2011. Accessed June 18, 2017.
2. Siempos II, Kopterides P, Tsangaris I, Dimopoulou I, Armaganidis AE. Impact of catheter-related bloodstream infections on the mortality of critically ill patients: A meta-analysis. Crit Care Med. 2009;37(7):2283-2289
3. Alliance of Wound Care Stakeholders 3/25/2020 https://iwoundsnews.com/alliance-of-wound-care-stakeholderswound-care-covid-19/
*3M™ Prevena™ 125 and 3M™ Prevena™ Plus 125 Therapy Units manage the environment of closed surgical incisions and remove fluid away from the surgical incision via the application of -125mmHg continuous negative pressure. When used with legally marketed compatible dressings, Prevena 125 and Prevena Plus 125 Therapy Units are intended to aid in reducing the incidence of seroma and, in patients at risk for post-operative infections, aid in reducing the incidence of superficial surgical site infection in Class I and II wounds.
The effectiveness of 3M™ Prevena™ Therapy in reducing the incidence of SSIs and seroma in all surgical procedures and populations has not been demonstrated. See full indications for use and limitations at 3M.com. -
Partnering to help reduce the total cost
Our products can help reduce length of patient stays and out-of-pocket costs.
- Data from a randomized controlled trial with at-risk patients showed that 3M™ Prevena™ Therapy significantly reduced the risk of 90-day surgical site complications (SSCs) and readmissions, when compared with the current standard of care (SOC). In fact, the evidence supporting the efficacy of Prevena Therapy was so strong that the study was terminated before its planned completion.¹
- 3M™ Attest™ Sterilization Solutions can help standardize and streamline workflows to reduce costly OR delays.²ᵃᵇᶜ
- One study showed using 3M™ Veraflo™ Therapy compared to NPWT alone can potentially save $33,338 per patient.³
References:
1. Higuera-Rueda C, Emara AK, Nieves-Malloure Y, Klika AK, Cooper HJ, Cross MB, Guild GN, Nam D, Nett M, Scuderi GR, Cushner FD, Piuzzi NS, Silverman RP. The Effectiveness of Closed Incision Negative Pressure Therapy versus Silver-Impregnated Dressings in Mitigating Surgical Site Complications in High-Risk Patients after Revision Knee Arthroplasty: The PROMISES Randomized Controlled Trial. J Arthroplasty (2021), doi: https://doi.org/10.1016/j.arth.2021.02.076
2a. Wong, Janice, and Kathleen Joy Khu. "Delays in the Operating Room: Signs of an Imperfect System." Canadian Journal of Surgery June 53.3 (2010): 189-95.
2b. Rosenthal, Thomas. “What is a Minute Worth in the OR?” OR Management News, June 6th, 2018, https://www.ormanagement.net/Clinical-News/Article/06-18/What-Is-a-Minute-Worth-in-the-OR-/48791
2c. Anderson DJ, Kaye KS, Chen LF, et al. Clinical and financial outcomes due to methicillin resistant Staphylococcus aureus surgical site infection: a multi-centered matched outcomes study. PLoS ONE. 2009;4e8305.
3. Kim, PJ, Lookess, S, Bongards, C, Griffin, LP, Gabriel, A. Economic model to estimate cost of negative pressure wound therapy with instillation vs control therapies for hospitalised patients in the United States, Germany, and United Kingdom. Int Wound J. 2021;1-7.doi:10.1111/iwj.13689
NOTE: Specific indications, limitations, contraindications, warnings, precautions and safety information exist for these products and therapies. Please consult a clinician and product instructions for use prior to application. Rx only. -
Partnering to help reduce the total cost
Our products can help reduce length of patient stays and out-of-pocket costs.
- Data from a randomized controlled trial with at-risk patients showed that 3M™ Prevena™ Therapy significantly reduced the risk of 90-day surgical site complications (SSCs) and readmissions, when compared with the current standard of care (SOC). In fact, the evidence supporting the efficacy of Prevena Therapy was so strong that the study was terminated before its planned completion.¹
- 3M™ Attest™ Sterilization Solutions can help standardize and streamline workflows to reduce costly OR delays.²ᵃᵇᶜ
- One study showed using 3M™ Veraflo™ Therapy compared to NPWT alone can potentially save $33,338 per patient.³
References:
1. Higuera-Rueda C, Emara AK, Nieves-Malloure Y, Klika AK, Cooper HJ, Cross MB, Guild GN, Nam D, Nett M, Scuderi GR, Cushner FD, Piuzzi NS, Silverman RP. The Effectiveness of Closed Incision Negative Pressure Therapy versus Silver-Impregnated Dressings in Mitigating Surgical Site Complications in High-Risk Patients after Revision Knee Arthroplasty: The PROMISES Randomized Controlled Trial. J Arthroplasty (2021), doi: https://doi.org/10.1016/j.arth.2021.02.076
2a. Wong, Janice, and Kathleen Joy Khu. "Delays in the Operating Room: Signs of an Imperfect System." Canadian Journal of Surgery June 53.3 (2010): 189-95.
2b. Rosenthal, Thomas. “What is a Minute Worth in the OR?” OR Management News, June 6th, 2018, https://www.ormanagement.net/Clinical-News/Article/06-18/What-Is-a-Minute-Worth-in-the-OR-/48791
2c. Anderson DJ, Kaye KS, Chen LF, et al. Clinical and financial outcomes due to methicillin resistant Staphylococcus aureus surgical site infection: a multi-centered matched outcomes study. PLoS ONE. 2009;4e8305.
3. Kim, PJ, Lookess, S, Bongards, C, Griffin, LP, Gabriel, A. Economic model to estimate cost of negative pressure wound therapy with instillation vs control therapies for hospitalised patients in the United States, Germany, and United Kingdom. Int Wound J. 2021;1-7.doi:10.1111/iwj.13689
NOTE: Specific indications, limitations, contraindications, warnings, precautions and safety information exist for these products and therapies. Please consult a clinician and product instructions for use prior to application. Rx only. -
Enhancing your reputation in the community
We support you during the entire patient healing journey.
- In 2020 and 2021, customers recognized 3M's negative pressure wound therapy products and services as having a Net Promoter Score in excess of 70*. This score measures the willingness of customers to recommend a company's products or services to others.
* The Net Promoter Score is an index ranging from -100 to 100. Learn more. 3M data on file.
- In a retrospective analysis of 4,739 acute and chronic wounds,** patients who began 3M™ V.A.C.® Therapy early vs. late experienced:
- Shorter time to reach significant wound surface area reduction.¹ᵃ
- Reduced homecare length of stay for surgical wounds and pressure injuries.¹ᵇ
- In a nonrandomized prospective study, 100% (n=9) of patients (who were able to report pain) experienced a reduction in pain when using 3M™ Cavilon™ Advanced Skin Protectant.²
*3M™ Cavilon™ Advanced Skin Protectant is not an analgesic..
- We can help protect patients and clinicians with respiratory solutions, facilitating your emergency preparedness planning.
- We provide education and training in 3M sterilization assurance and cleaning monitoring products and their use facility sterilization and cleaning practices.
- In a post-market, randomized, open-label, multicenter study, patients treated with 3M™ Prevena™ Therapy* were 4X³ less likely to experience a post-operative 90-day surgical site complication. And, 3X³ less likely to be readmitted compared to the standard of care group.⁴
Learn more about study design, purpose and methods here.
References:
1a. Miller Mikolajczyk C, MStat RJ. Real world use: comparing early versus late initiation of negative pressure wound therapy on wound surface area reduction in patients at wound care clinics. Poster presented at The Wound Ostomy and Continence Nurses Society Annual Conference, June 22 26, 2013. Seattle, Washington. For acute wounds, “early” was defined as NPWT being instituted within 7 days of first WCC, while “late” was defined as NPWT being instituted after 7 days post WCC admission. For chronic wounds, the “early” vs “late” threshold was defined as 30 days. Significant wound surface area (WSA) reduction was defined in the study as a reduction of 75% WSA from initial visit.
1b. BaharestaniMM. Driver VR. Optimizing clinical and cost effectiveness with early intervention of V.A.C.® Therapy. Ostomy Wound Manage.2008;54(11 Suppl):1-15.
2. Brennan, Mary R.; Milne, Catherine T.; Agrell-Kann, Marie; Ekholm, Bruce P. Clinical Evaluation of a Skin Protectant for the Management of Incontinence Associated Dermatitis: An Open-Label, Nonrandomized, Prospective Study. J of Wound, Ostomy & Continence Nursing. 2017. 44(2):172-180.
3. Calculation(s) are derived based on relative patient group incidence rate reported in this study. Statistically significant (p=<0.05)
4. Higuera-Rueda CA, Emara AK, Nieves-Malloure Y, Klika AK, Cooper HJ, Cross MB, Guild GN, Nam D, Nett MP,Scuderi GR, Cushner FD, Piuzzi NS, Silverman RP. J. Arthroplasty 2021; doi: 10.1016/j.arth.2021.02.076
3M™ Prevena™ 125 and 3M™ Prevena™ Plus 125 Therapy Units manage the environment of closed surgical incisions and remove fluid away from the surgical incision via the application of -125mmHg continuous negative pressure. When used with legally marketed compatible dressings, Prevena 125 and Prevena Plus 125 Therapy Units are intended to aid in reducing the incidence of seroma and, in patients at risk for post-operative infections, aid in reducing the incidence of superficial surgical site infection in Class I and II wounds.
*The effectiveness of Prevena Therapy in reducing the incidence of SSIs and seroma in all surgical procedures and populations has not been demonstrated. See full indications for use and limitations at 3M.com.
**The US Wound Registry was used in this retrospective analysis that examined 4,739 acute and chronic wounds (56.7% and 43.3%, respectively) that received NPWT, from 3,604 patients treated in 56 outpatient WCCs from 11-Nov-2000 through 16-Jul-2010. For Acute Wounds, median days from first visit to 75% Wound Surface Area (WSA) reduction was 40.4 days for early group vs. 81.6 days for late group, or 1/2 the time for the early group (p<0.0001). For Chronic Wounds, median days from first visit to 75% WSA reduction was 96.4 days for early group vs. 274.6 days for late group, or 1/3 the time for the early group (p<0.0001). - In 2020 and 2021, customers recognized 3M's negative pressure wound therapy products and services as having a Net Promoter Score in excess of 70*. This score measures the willingness of customers to recommend a company's products or services to others.
-
Positively impacting patient preventionWe can help reduce the risk of infections and readmissions.
- Help reduce the risk of cross contamination¹
- 3M™ Tegaderm™ CHG Chlorhexidine Gluconate I.V. Securement Dressing is intended to reduce the risk of catheter related bloodstream infections (CRBSIs)²
- 3M™ Prevena™ Therapy* has been clinically demonstrated to aid in reducing the incidence of superficial surgical site infection in patients at high risk for post-operative infections with Class I and Class II wounds.
- We can help reduce the risk of surgical complications through an evidence-based approach to the perioperative journey.
- Studies have shown that 3M™ Veraflo™ Therapy through repeated wound cleansing and NPWT can help reduce the likelihood of complications resulting from a stalled wound.³
References:
1. CDC Vitalsigns making health care safer: Reducing bloodstream infections. Centers for Disease Control and Prevention Web site. https://www.cdc.gov/vitalsigns/pdf/2011-03- vitalsigns.pdf Published March, 2011. Accessed June 18, 2017.
2. Siempos II, Kopterides P, Tsangaris I, Dimopoulou I, Armaganidis AE. Impact of catheter-related bloodstream infections on the mortality of critically ill patients: A meta-analysis. Crit Care Med. 2009;37(7):2283-2289
3. Alliance of Wound Care Stakeholders 3/25/2020 https://iwoundsnews.com/alliance-of-wound-care-stakeholderswound-care-covid-19/
*3M™ Prevena™ 125 and 3M™ Prevena™ Plus 125 Therapy Units manage the environment of closed surgical incisions and remove fluid away from the surgical incision via the application of -125mmHg continuous negative pressure. When used with legally marketed compatible dressings, Prevena 125 and Prevena Plus 125 Therapy Units are intended to aid in reducing the incidence of seroma and, in patients at risk for post-operative infections, aid in reducing the incidence of superficial surgical site infection in Class I and II wounds.
The effectiveness of 3M™ Prevena™ Therapy in reducing the incidence of SSIs and seroma in all surgical procedures and populations has not been demonstrated. See full indications for use and limitations at 3M.com. -
Partnering to help reduce the total costOur products can help reduce length of patient stays and out-of-pocket costs.
- Data from a randomized controlled trial with at-risk patients showed that 3M™ Prevena™ Therapy significantly reduced the risk of 90-day surgical site complications (SSCs) and readmissions, when compared with the current standard of care (SOC). In fact, the evidence supporting the efficacy of Prevena Therapy was so strong that the study was terminated before its planned completion.¹
- 3M™ Attest™ Sterilization Solutions can help standardize and streamline workflows to reduce costly OR delays.²ᵃᵇᶜ
- One study showed using 3M™ Veraflo™ Therapy compared to NPWT alone can potentially save $33,338 per patient.³
References:
1. Wong, Janice, and Kathleen Joy Khu. "Delays in the Operating Room: Signs of an Imperfect System." Canadian Journal of Surgery June 53.3 (2010): 189-95.
2a. Kim, PJ, Lookess, S, Bongards, C, Griffin, LP, Gabriel, A. Economic model to estimate cost of negative pressure wound therapy with instillation vs control therapies for hospitalised patients in the United States, Germany, and United Kingdom. Int Wound J. 2021;1-7.doi:10.1111/iwj.13689
2b. Rosenthal, Thomas. “What is a Minute Worth in the OR?” OR Management News, June 6th, 2018, https://www.ormanagement.net/Clinical-News/Article/06-18/What-Is-a-Minute-Worth-in-the-OR-/48791
2c. Anderson DJ, Kaye KS, Chen LF, et al. Clinical and financial outcomes due to methicillin resistant Staphylococcus aureus surgical site infection: a multi-centered matched outcomes study. PLoS ONE. 2009;4e8305.
3. Higuera-Rueda C, Emara AK, Nieves-Malloure Y, Klika AK, Cooper HJ, Cross MB, Guild GN, Nam D, Nett M, Scuderi GR, Cushner FD, Piuzzi NS, Silverman RP. The Effectiveness of Closed Incision Negative Pressure Therapy versus Silver-Impregnated Dressings in Mitigating Surgical Site Complications in High-Risk Patients after Revision Knee Arthroplasty: The PROMISES Randomized Controlled Trial. J Arthroplasty (2021), doi:
NOTE: Specific indications, limitations, contraindications, warnings, precautions and safety information exist for these products and therapies. Please consult a clinician and product instructions for use prior to application. Rx only. -
Enhancing your reputation in the communityWe support you during the entire patient healing journey.
In 2020 and 2021, customers recognized 3M’s negative pressure wound therapy products and services as having a Net Promoter Score in excess of 70*. This score measures the willingness of customers to recommend a company’s products or services to others.
* The Net Promoter Score is an index ranging from -100 to 100. Learn more. 3M data on file.- In a retrospective analysis of 4,739 acute and chronic wounds,** patients who began 3M™ V.A.C.® Therapy early vs. late experienced:
- Shorter time to reach significant wound surface area reduction¹ᵃ
- Reduced homecare length of stay for surgical wounds and pressure injuries¹ᵇ
- In a nonrandomized prospective study, 100% (n=9) of patients (who were able to report pain) experienced a reduction in pain when using 3M™ Cavilon™ Advanced Skin Protectant²
*3M™ Cavilon™ Advanced Skin Protectant is not an analgesic.- We can help protect patients and clinicians with respiratory solutions, facilitating your emergency preparedness planning
- We provide education and training in 3M sterilization assurance and cleaning monitoring products and their use facility sterilization and cleaning practices.
- In a post-market, randomized, open-label, multicenter study, patients treated with 3M™ Prevena™ Therapy* were 4X³ less likely to experience a post-operative 90-day surgical site complication. And, 3X³ less likely to be readmitted compared to the standard of care group.⁴
Learn more about study design, purpose and methods here -
https://multimedia.3m.com/mws/media/2186970O/3m-prevena-therapy-promises-clinical-evidence-summary-anz.pdf (PDF, 195 KB)
3M™ Prevena™ 125 and 3M™ Prevena™ Plus 125 Therapy Units manage the environment of closed surgical incisions and remove fluid away from the surgical incision via the application of -125mmHg continuous negative pressure. When used with legally marketed compatible dressings, Prevena 125 and Prevena Plus 125 Therapy Units are intended to aid in reducing the incidence of seroma and, in patients at risk for post-operative infections, aid in reducing the incidence of superficial surgical site infection in Class I and II wounds.
*The effectiveness of Prevena Therapy in reducing the incidence of SSIs and seroma in all surgical procedures and populations has not been demonstrated. See full indications for use and limitations at 3M.com.References:
1a. Miller Mikolajczyk C, MStat RJ. Real world use: comparing early versus late initiation of negative pressure wound therapy on wound surface area reduction in patients at wound care clinics. Poster presented at The Wound Ostomy and Continence Nurses Society Annual Conference, June 22 26, 2013. Seattle, Washington. For acute wounds, “early” was defined as NPWT being instituted within 7 days of first WCC, while “late” was defined as NPWT being instituted after 7 days post WCC admission. For chronic wounds, the “early” vs “late” threshold was defined as 30 days. Significant wound surface area (WSA) reduction was defined in the study as a reduction of 75% WSA from initial visit.
1b. BaharestaniMM. Driver VR. Optimizing clinical and cost effectiveness with early intervention of V.A.C.® Therapy. Ostomy Wound Manage.2008;54(11 Suppl):1-15.
2. Brennan, Mary R.; Milne, Catherine T.; Agrell-Kann, Marie; Ekholm, Bruce P. Clinical Evaluation of a Skin Protectant for the Management of Incontinence Associated Dermatitis: An Open-Label, Nonrandomized, Prospective Study. J of Wound, Ostomy & Continence Nursing. 2017. 44(2):172-180.
3. Calculation(s) are derived based on relative patient group incidence rate reported in this study. Statistically significant (p=<0.05)
4. Higuera-Rueda CA, Emara AK, Nieves-Malloure Y, Klika AK, Cooper HJ, Cross MB, Guild GN, Nam D, Nett MP,Scuderi GR, Cushner FD, Piuzzi NS, Silverman RP. J. Arthroplasty 2021; doi: 10.1016/j.arth.2021.02.076**The US Wound Registry was used in this retrospective analysis that examined 4,739 acute and chronic wounds (56.7% and 43.3%, respectively) that received NPWT, from 3,604
patients treated in 56 outpatient WCCs from 11-Nov-2000 through 16-Jul-2010. For Acute Wounds, median days from first visit to 75% Wound Surface Area (WSA) reduction
was 40.4 days for early group vs. 81.6 days for late group, or 1/2 the time for the early group (p<0.0001). For Chronic Wounds, median days from first visit to 75% WSA reduction
was 96.4 days for early group vs. 274.6 days for late group, or 1/3 the time for the early group (p<0.0001).
Listen up - Inside Angle podcast
Conversations at the heart of moving health care forward, shared through the voices and insights of 3M experts and beyond.
-
When U.S. business leaders noticed that their employees in other countries were getting better care and outcomes for less cost than in the U.S., they knew something needed to change. Enter the Primary Care Collaborative (PCC), a not-for-profit, multi-stakeholder organization dedicated to sharing best practices to support the growth of high performing primary care. Ann Greiner, president and CEO of the PCC, describes the organization’s work and commitment to finding a solution to the current state of primary care in the U.S.
-
The health care industry is changing. Is your organization keeping up? Best selling author, inventor and technologist Nicholas Webb explores the trends disrupting the current state of health care and details three things that hospitals and clinics can do to prepare for survival.
-
Founded in 1963 as a health and beauty store, CVS has evolved over its 50-year history, but always maintained a focus on making health care local and accessible. In this episode, Dr. Dan Knecht of CVS Health discusses how the company’s 2018 acquisition of Aetna is driving innovative, new programs where CVS clinical pharmacists are applying health plan data to identify gaps in care, improve medication adherence, and help patients manage chronic conditions like diabetes–all with the goal of helping people make progress on their unique health journeys.
The Power of We
Together, we can do more than provide care. We can help transform outcomes.
